ramatroban has been researched along with Cardiovascular Stroke in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altavilla, D; Campo, GM; Canale, P; Caputi, AP; Faggiotto, A; Ioculano, M; Oriti, S; Saitta, A; Squadrito, F; Zingarelli, B | 1 |
| Fiedler, VB; Perzborn, E; Seuter, F | 2 |
| Böshagen, H; Fiedler, VB; Perzborn, E; Rosentreter, U; Seuter, F | 1 |
4 other study(ies) available for ramatroban and Cardiovascular Stroke
| Article | Year |
|---|---|
Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury.
Topics: Animals; Carbazoles; Creatine Kinase; Hemodynamics; Leukocytes; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Peroxidase; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane; Sulfonamides; Thromboxane A2 | 1993 |
Protective effect of a novel thromboxane antagonist, BAY-U3405, on canine myocardial damage after coronary artery occlusion and reperfusion.
Topics: Animals; Carbazoles; Coronary Circulation; Dogs; Female; Hemodynamics; Humans; Infusions, Intravenous; Ligation; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Sulfonamides; Thromboxanes; Time Factors; Ventricular Fibrillation | 1991 |
Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Carbazoles; Coronary Disease; Coronary Vessels; Disease Models, Animal; Dogs; Hemodynamics; Myocardial Infarction; Prostaglandin Endoperoxides, Synthetic; Sulfonamides; Swine; Thromboxanes; Vasoconstriction | 1990 |
Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
Topics: Animals; Blood Pressure; Carbazoles; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Dogs; Electric Stimulation; Female; Fibrinolytic Agents; Heart Rate; Humans; In Vitro Techniques; Male; Myocardial Infarction; Sulfonamides; Thromboxane A2 | 1989 |